Pentixapharm Holding (PTP) Stock Overview
A clinical-stage biopharmaceutical company, develops radiopharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PTP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pentixapharm Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.87 |
| 52 Week High | €5.15 |
| 52 Week Low | €1.46 |
| Beta | 0 |
| 1 Month Change | 7.98% |
| 3 Month Change | -12.30% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.93% |
Recent News & Updates
Shareholder Returns
| PTP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 23.9% | -0.5% | -0.3% |
| 1Y | n/a | -4.8% | 14.7% |
Return vs Industry: Insufficient data to determine how PTP performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how PTP performed against the German Market.
Price Volatility
| PTP volatility | |
|---|---|
| PTP Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: PTP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PTP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 64 | Dirk Pleimes | www.pentixapharm.com |
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors.
Pentixapharm Holding AG Fundamentals Summary
| PTP fundamental statistics | |
|---|---|
| Market cap | €46.29m |
| Earnings (TTM) | -€20.11m |
| Revenue (TTM) | n/a |
Is PTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTP income statement (TTM) | |
|---|---|
| Revenue | -€1.13m |
| Cost of Revenue | €6.49m |
| Gross Profit | -€7.61m |
| Other Expenses | €12.50m |
| Earnings | -€20.11m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 674.75% |
| Net Profit Margin | 1,782.28% |
| Debt/Equity Ratio | 0% |
How did PTP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/21 16:40 |
| End of Day Share Price | 2025/09/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pentixapharm Holding AG is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.